Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caelyx Monotherapy in Platinum-Resistant Ovarian Cancer
NCT00727961Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2004
- Primary completion
- Jan 2008
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
01
Overview
Phase 4, open-label, single-arm trial of pegylated liposomal doxorubicin in epithelial ovarian cancer (EOC), sponsored by Merck & Co. Primary endpoints: Number of Participants With Complete Response, Number of Participants With Partial Response and 2 more. Started Nov 2004; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NCT00727961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00727961.